This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Diagnosing testosterone deficiency (TD)

Starting the conversation with your patients

Tools for screening

The Androgen Deficiency in Ageing Males (ADAM) questionnaire and the Ageing Males’ Symptoms (AMS) scale are two clinically validated tools, to help quickly evaluate the possible presence, and severity, of TD symptoms.

The Androgen Deficiency in Ageing Males (ADAM) questionnaire

The ADAM questionnaire is a clinically validated patient questionnaire to assist in the identification of men over 40 years who may be suffering from TD (a blood test should be used to confirm diagnosis following ADAM screening).1,2 Questionnaires can offer a simple solution for patients that find discussions around their personal health concerns difficult.

‘Yes’ answers to:1

  • question 1 or question 7; or
  • any three other questions;

denotes a positive result and indicates a need for further clinical investigation.

The ADAM questionnaire has 97% sensitivity for TD3

Request an ADAM questionnaire tear-off pad from your Besins Healthcare representative today. 

The Ageing Males’ Symptoms (AMS) scale

The AMS scale is a quantitative 1–5 scale to assess presence and severity of TD symptoms.4 It consists of 17-questions and is beneficial in both diagnosing TD and in assessing clinical response to therapy.4

Interpreting the AMS scale:5

Total score
<26No/little complaints
The AMS scale has 83% sensitivity for TD3

Review your patients’ symptoms

Support patient self-management with the T Track app

Encourage your patients to review their symptoms using the Ageing Males’ Symptom (AMS) scale in the T Track app and monitor their progress over time.

T Track app available for both iOS and Android phones.

Support patient self-management with the T Track app


  1. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239–1242.
  2. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.
  3. Morley JE, Perry HM, Kevorkian RT, et al. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53(4):424–429.
  4. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.
  5. Moore C, Huebler D, Zimmermann T, et al. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80–87.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: